179 related articles for article (PubMed ID: 30474718)
1. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
2. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
3. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
[TBL] [Abstract][Full Text] [Related]
4. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Amin HM; Yang Y; Shen Y; Estey EH; Giles FJ; Pierce SA; Kantarjian HM; O'Brien SM; Jilani I; Albitar M
Leukemia; 2005 Sep; 19(9):1567-72. PubMed ID: 16049515
[TBL] [Abstract][Full Text] [Related]
5. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).
Bennett JM; Tuechler H; Aul C; Strupp C; Germing U
Leuk Res; 2016 Aug; 47():63-9. PubMed ID: 27258735
[TBL] [Abstract][Full Text] [Related]
6. Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Chaudhary AK; Chaudhary S; Ghosh K; Shanmukaiah C; Nadkarni AH
Asian Pac J Cancer Prev; 2016; 17(3):1519-29. PubMed ID: 27039800
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
9. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
Alkharabsheh O; Patnaik MM; Gangat N; Begna KH; Alkhateeb HB; Shah MV; Hogan WJ; He R; Greipp P; Nguyen PL; Litzow MR; Al-Kali A
Ann Hematol; 2020 Mar; 99(3):513-518. PubMed ID: 31974678
[TBL] [Abstract][Full Text] [Related]
10. Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes.
Ogata K; Satoh C; Hyodo H; Tamura H; Dan K; Yoshida Y
Leuk Res; 2004 Nov; 28(11):1171-5. PubMed ID: 15380341
[TBL] [Abstract][Full Text] [Related]
11. [Clinical analysis in a cohort of 102 patients with myelodysplastic syndrome characterized by erythroid hyperplasia].
Yu Y; Sun AN; Chen SN; Wang QR; Zhang TT; Wu DP
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):29-33. PubMed ID: 28056320
[No Abstract] [Full Text] [Related]
12. Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.
Chen Y; Pourabdollah M; Atenafu EG; Tierens A; Schimmer A; Chang H
Leuk Res; 2017 Oct; 61():39-43. PubMed ID: 28886412
[TBL] [Abstract][Full Text] [Related]
13. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
[TBL] [Abstract][Full Text] [Related]
14. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification.
Wang SA; Tang G; Fadare O; Hao S; Raza A; Woda BA; Hasserjian RP
Mod Pathol; 2008 Nov; 21(11):1394-402. PubMed ID: 18839018
[TBL] [Abstract][Full Text] [Related]
15. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
16. Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes.
Balduini CL; Guarnone R; Pecci A; Centenara E; Ascari E
Leukemia; 1998 Oct; 12(10):1655-6. PubMed ID: 9766515
[No Abstract] [Full Text] [Related]
17. Counting bone marrow blasts as a percentage of nonerythroid cells improves the prognostic evaluation of MDS with erythroid predominance.
Yu Y; Zhang T; Wang Q; Wu D; Pan J; Liang J; Chen S; Sun A
Am J Hematol; 2017 Apr; 92(4):E55-E57. PubMed ID: 28133867
[No Abstract] [Full Text] [Related]
18. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Ardanaz MT; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
Mod Pathol; 2016 Dec; 29(12):1541-1551. PubMed ID: 27562492
[TBL] [Abstract][Full Text] [Related]
19. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
[TBL] [Abstract][Full Text] [Related]
20. [Expression of insulin-like growth factor receptor type I in marrow nucleated cells from hematologic malignancies and its anti-apoptotic effect].
He Q; Li X; Tao Y; Liu YZ; Yang LP; Ying SX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):483-7. PubMed ID: 15972147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
